Revvity Signals || Signals One™

EDITORIAL SECTION

  • STRATEGY

    Smarter Pharma

    Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products

  • EXPERT Talk

    Compliance to Competitive Advantage in Pharma Supply

    Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser

KNOWLEDGE BANK

  • Articles

    Innovative Pricing Models in the EU: Making Medicines Affordable for All

    Pricing policies are important determinants in delivering sufficiently cheap medicines in all the member nations of the EU High costs of meeting the required medical care together with arising independent differentiated technological improvements have rendered exhausted pricing structures as uncompetitive tools for fairness New mechanisms of pricing have been introduced

    From Lab to Market: The Journey of a New Drug

    The process of synthesizing a new drug takes many years and several phases and all of them are important for the drug safety and efficacy Which from the first identification in a lab to the final approval of use by the public is a process that takes over years and this involves work done by scientists various agencies and other health care givers

    How Predictive Maintenance Reduces Downtime in Pharma Plants

    The pharmaceutical industry is always under stress to enhance the reliability of the production adherence to the regulations and quality of the products without raising the prices and to maintain a continuous supply Machinery malfunctions are not merely a setback in this highstakes game they may compromise batch integrity postpone life and death treatments and put pressure on the market promises

    Combination Immunotherapy Trials: Designing the Next Generation of Cancer Drugs

    For most of the past ten years the prevailing strategy in immunooncology was addition Checkpoint blockade delivered durable remissions in a minority of patients the intuitive fix was to attach a second agent to a PD or PDL backbone and watch whether response rates moved

    Circular Logistics: A Strategic Advantage for U.S. Pharmaceutical Supply Chains in an Era of Uncertainty

    Temperaturerelated failures are estimated to cost the industry billion annually highlighting a nonnegotiable requirement for reliability product integrity and regulatory compliance For manufacturers

    Breaking Down Barriers: Advancements in Biodegradable Drug Delivery

    In todays world where sustainability is a top priority breaking down barriers to a greener future is crucial One area where advancements are being made is in the field of biodegradable drug delivery

TOP ARTICLES

  • 1

    From Lab to Market: The Journey of a New Drug

    Sarah Richards

    The article "From Lab to Market: The ‘The Journey of a New Drug’ is an account of stages of new drug development process which includes identification of the drug, testing, clinical t...

press releases Read more...

Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia

Cardiff Oncology Inc a clinicalstage biotechnology company leveraging PLK inhibition to develop novel cancer therapies today announced that the US Food and Drug Administration FDA has granted Orphan Drug Designation to onvansertib for the treatment of patients with chronic myelomonocytic leukemia

Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer

Geneos Therapeutics a clinical stage biotherapeutics company focused on the development of neoantigenbased personalized immunotherapy for cancer PIC today announced the initiation of its Phase randomized clinical trial NCT in patients with highrisk hepatocellular carcinoma HCC liver cancer

Medicovestor Announces FDA Fast Track Designation for MC001, Its First-in-Class Chemoimmunotherapy ADC for Pancreatic Cancer

Medicovestor Inc today announced that the US Food and Drug Administration FDA has granted Fast Track designation to MC its lead investigational firstinclass chemoimmunotherapy antibodydrugconjugate ADC for pancreatic cancer

Orogen Therapeutics Announces Selection of Two Development Candidates for Immune Diseases, Potential Best-in-Class Oral IL-17 and JAK1/TYK2 Small Molecule Inhibitors

Orogen Therapeutics Inc announced the selection of two development candidates DCs ORO and ORO potential bestinclass oral small molecule inhibitors of IL and JAKTYK respectively Both DCs have completed extensive nonclinical studies to demonstrate attractive

21 - 23

Oct 2026

21 - 22

Oct 2026

22 - 23

Oct 2026

PDA Aseptic Symposium 2026

Congress Square Nakanoshima, O...

26 - 28

Oct 2026

ACHEMA Middle East 2026

RICEC, Riyadh, KSA, Saudi Arab...

26 - 28

Oct 2026

World Orphan Drug Congress

RAI, Amsterdam, Netherlands

27 - 28

Oct 2026

Pharma Manufacturing & Automation Convention 2026

Novotel Hyderabad Airport, Ind...

28 - 30

Oct 2026

02 - 04

Nov 2026

Pharma Forum EMEA 2026

Dom Pedro Lisboa Hotel, Lisbon...

LATEST NEWS Read more...

AI Proteins Announces Research Collaboration and License Agreement With Astellas Pharma to Discover and Develop Novel Miniprotein-Based Therapeutics Valued at Over $400 Million

AI Proteins Inc a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins today announced it has entered into a Research Collaboration and License Agreement with Astellas Innovation Management LLC an affiliate of Astellas Pharma Inc TSE to discove...

Okomera Announces Trade Agreement with Servier to Use Tumor Miniaturization Technology in Cancer Research

Okomera a TechBio company that personalizes cancer management with its technology combining minivatars tumor microfluidics and AI imaging today announced the signing of a commercial agreement with Servier an independent international pharmaceutical group

ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics

ScionxBio a privately held preclinicalstage biotechnology company pioneering nextgeneration mRNA therapeutics distinguished by their extended durability profile today announced that it has entered into a worldwide strategic collaboration and licensing agreement with Sanofi

Takara Bio USA Partners with SPT Labtech to Deliver Automation-Ready NGS Library Preparation Technologies

Takara Bio USA Inc a wholly owned subsidiary of Takara Bio Inc and SPT Labtech today announced their partnership to deliver validated automated library preparation workflows that combine Takara Bio nextgeneration sequencing NGS library preparation chemistries with SPT Labtechs firefly liquid handlin...

AtomVie Global Radiopharma Announces Strategic Partnership with Jubilant Radiopharma to Strengthen Logistics and Distribution in Clinical Trials

AtomVie Global Radiopharma a global contract developer and manufacturer CDMO for radiopharmaceuticals today announced a strategic partnership with Jubilant DraxImage Inc operating as Jubilant Radiopharma Jubilant Radiopharma to provide logistics approval and lastmile distribution services to support

Transcripta Bio Announces Research Collaboration to Advance Discovery of New ALS Treatments

Transcripta Bio an AIpowered drug discovery company focused on neurological and neuromuscular diseases today announced a research collaboration and licensing agreement with Mayo Clinic centered on amyotrophic lateral sclerosis ALS a fatal neurodegenerative disease with few effective treatments